Biotech Stock Mailbag: Mela, Osiris, Talon
BOSTON (TheStreet) -- This week's Biotech Stock Mailbag opens by noting the passing of Genta, which announced plans to file for Chapter 7 bankruptcy this week after 13 years and $1.3 billion in wasted investor capital. We'll miss you Ray Warrell, you taught a lot of investors -- and a certain journalist -- how to be skeptical of biotech zeroes. Thank you!
A housekeeping note: The Mailbag is taking a two-week August hiatus so I can enjoy some vacation time. The column will return Aug. 24.
Moving on to your emails and tweets: ...Click to view a price quote on MELA. Click to research the Health Services industry.
Original Article: Biotech Stock Mailbag: Mela, Osiris, TalonNEXT ARTICLE